SCA
TOVX icon

Snowden Capital Advisors’s Theriva Biologics TOVX Stock Holding History

Snowden Capital Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-185
Closed -$14.9K – 575
2020
Q1 		$14.9K Hold
185
– – ﹤0.01% 520
2019
Q4 		$23.5K Hold
185
– – ﹤0.01% 579
2019
Q3 		$21K Buy
+185
New +$22.3K ﹤0.01% 511

Other funds holding TOVX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Snowden Capital Advisors's TOVX Position: Q2 2020 in Review

Snowden Capital Advisors sold out of Theriva Biologics (TOVX) in Q2 2020, closing a stake of 185 shares — an estimated $14.9K sold.

Snowden Capital Advisors first reported a position in TOVX in Q3 2019 and held it in 3 quarters. The position peaked at $23.5K in Q4 2019. 19 funds tracked by Wall St. Rank hold TOVX as of Q2 2020.

  • Snowden Capital Advisors reported no remaining Theriva Biologics position as of Q2 2020 after selling out during the quarter.
  • Snowden Capital Advisors sold 185 Theriva Biologics shares in Q2 2020, an estimated $14.9K.
  • Snowden Capital Advisors first reported a position in Theriva Biologics in Q3 2019 and held it in 3 quarters.
  • Snowden Capital Advisors's Theriva Biologics position peaked at $23.5K in Q4 2019.
  • 19 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2020.

Based on Snowden Capital Advisors's 13F filing for Q2 2020, filed 8 Jan 2024.